Loading clinical trials...

Nebivolol and Endothelial Regulation of Fibrinolysis (NERF) | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)

Nebivolol and Endothelial Regulation of Fibrinolysis

NCT01595516•University of Colorado, Boulder

Summary

The investigators hypothesize that nebivolol will improve endothelial t-PA release in adult humans with elevated blood pressure to a greater extent than either metoprolol or placebo. The investigators further hypothesize that the improvement in the capacity of the vascular endothelium to release t-PA with nebivolol is mediated, in part, by the compound's antioxidant properties.

Eligibility

Age

45 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Subjects will be men and women of all races and ethnic backgrounds aged 45-65 years.
•Subjects will be prehypertensive/hypertensive defined as resting systolic blood pressure \>125 mmHg and \<160 mmHg and/or diastolic \>80 mmHg and \<100 mmHg.
•All of the women in the study will be postmenopausal and not receiving hormone replacement therapy (HRT) currently or in the preceding 3-year period.
•Candidates will be sedentary as determined from the Stanford Physical Activity Questionnaire (\<35 kcal/wk) and will not have engaged in any program of regular physical activity for at least 1 year prior to the study.

Exclusion Criteria

•Candidates who smoke (currently or in the past 7 years), report more than low-risk alcohol consumption as defined as no more than 14 standard drinks/wk and no more than 4 standard drinks/day for men and 7 standard drinks/wk and 3 standard drinks/day for women (a standard drink is defined as 12 ounces of beer, 5 ounces of wine, 1½ ounces of 80-proof distilled spirits).
•Potential candidates who are taking cardiovascular-acting (i.e. statins, blood pressure medication and aspirin) medications will not be eligible.
•Fasting plasma glucose \>126 mg/dL.
•Potential candidates with a resting heart rate of \< 50 beats/minute will be excluded.
•Use of hormone replacement therapy.
•In hypertensive subjects, a seated systolic blood pressure \>160 mmHg or a seated diastolic blood pressure \>100 mmHg will be excluded.

Locations (1)

UC-Boulder Clinical and Translational Research Center

Boulder, Colorado, United States

Key Dates

Start Date

February 1, 2012

Primary Completion Date

October 1, 2017

Completion Date

October 1, 2017

Last Updated

June 25, 2019

Enrollment

ACTUAL participants

Conditions

PrehypertensionHypertension

Interventions

Nebivolol

DRUG

Metoprolol

DRUG

Placebo

DRUG

Bradykinin

OTHER

Saline

OTHER

Vitamin C

OTHER

Natural History of Noncirrhotic Portal Hypertension

NCT02417740

Cystic FibrosisImmunologic Deficiency Syndrome+3 more

View study

RECRUITING

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

NCT07480265

Hypertension (HTN)Hyperhomocysteinemia+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 25, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)

Inclusion Criteria

Exclusion Criteria

Natural History of Noncirrhotic Portal Hypertension

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication

Penn Medicine Healthy Heart

Preliminary Human Trials of F230 Tablets